BIOSTEM TECHNOLOGIES Business Summary

BioStem Technologies (BSEM) is a vertically integrated regenerative medicine company specializing in the development, manufacture, and commercialization of placental-derived allografts for advanced wound care. The company generates revenue through the direct sale of its proprietary perinatal tissue products—including Vendaje®, Vendaje AC®, and AmnioWrap2™—which are processed using its validated BioREtain® method to maintain the tissue’s natural biological properties. Its primary business segments include non-acute chronic wound care (treating pressure, diabetic, and venous ulcers) and a newly expanded acute care surgical segment following the January 2026 acquisition of BioTissue Holdings’ surgical and wound care business. BioStem competes with major players like MiMedx Group (MDXG), Organogenesis Holdings (ORGO), and Smith & Nephew (SNNU), positioning itself as a high-efficiency manufacturer with gross margins near 90% and a strategic focus on capturing market share within the VA and Medicaid sectors. The company was co-founded in 2014 by CEO and Chairman Jason Matuszewski and COO Andrew Van Vurst, both of whom remain central to its leadership. Matuszewski, a mechanical engineer by training, leverages a background in process optimization from SC Johnson and Nemak to drive the company’s lean manufacturing model, while Van Vurst, a U.S. Marine Corps veteran, manages the firm’s FDA-registered and AATB-accredited production facilities. The executive team is further strengthened by CFO Brandon Poe, who brings over 25 years of life sciences financial leadership from roles at Genome Medical and Midi Health, and Chief Commercial Officer Barry Hassett, appointed in January 2026 to lead global sales expansion. The board of directors includes industry veterans such as Thomas Dugan, former CEO of Amniox Medical, and Patrick Daly, providing deep expertise in surgical biologics as the company pursues a planned Nasdaq uplisting in mid-2026.